Evropska unija - slovenščina - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemofilija a - antihemoragije - zdravljenje in preventivo za krvavitev pri bolnikih s hemofilija a (prirojeno faktor viii pomanjkljivost). ta pripravek ne vsebuje von willebrand dejavnik in zato ni navedeno v von willebrand je bolezen.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ivabradin - filmsko obložena tableta - ivabradin 7,5 mg / 1 tableta - ivabradin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

cefuroksim - prašek za raztopino za injiciranje/infundiranje - cefuroksim 1500 mg / 1 viala - cefuroksim

Evropska unija - slovenščina - EMA (European Medicines Agency)

bayer ag - rivaroksaban - arthroplasty, replacement; venous thromboembolism - antitrombotična sredstva - xarelto, co-daje z acetilsalicilne kisline (asa) samostojno ali s asa plus clopidogrel ali ticlopidine, je označen za preprečevanje atherothrombotic dogodkov pri odraslih bolnikih po akutni koronarni sindrom (acs) s povišano srčno biomarkerje. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. preprečevanje venska trombembolija (vte) pri odraslih bolnikih, ki so v postopku izbirni kirurški zamenjavi kolka ali kolena. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotična sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Evropska unija - slovenščina - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - limfom, b-celice - antineoplastična sredstva - polivy v kombinaciji z bendamustine in rituksimabom je indiciran za zdravljenje odraslih bolnikov z relapsed/ognjevzdržni razpršenih veliko b-celični limfom (dlbcl), ki niso kandidati za haematopoietic matičnih celic za presajanje. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).